Clinical Trial Finder
Immune Biomarker Study for Salivary Gland Carcinoma
Study Purpose
Aims of this study are analyses of tumor metabolome, tumor transcriptome and tumor proteome as well as of the immune infiltration, separated by histological entity. These data will subsequently be compared with the with the detailed immune status determined in the patient's peripheral blood and saliva using machine learning techniques, among others, to create a biomarker cluster for salivary gland tumors. These can be used in clinical routine. In addition, the investigators would like to study a subset of patients from freshly resected tumor organoids from freshly resected tumor tissue according to already established methods in order to mechanistic investigations of prognostic parameters.
Recruitment Criteria
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Inclusion Criteria:
1. Observational group.- - Initial diagnosis of a primary salivary gland carcinoma in the head and neck
region (no squamous cell carcinomas)
- Specimen collection from the center of the tumor when the primary tumor is
sufficiently large without that the pathological assessment is impaired.
2. Control group 1.- - Specimen collection from the center of the tumor when the primary tumor is
sufficiently large without that the pathological assessment is impaired.
3. Control group 2.- - functional diseases of the nose or ear (patients with the indication for
functional ear surgery and rhinoplasty)
- Specimen collection with sufficiently large resectate during a functional nose
surgery.
for all groups:Exclusion Criteria:
- - Patients who are represented by a legal guardian.
- Patients who are not suitable for participation in the study due to a language barrierTrial Details
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
Arms
: Observational Arm
Initial diagnosis of primary salivary gland carcinoma in the head and neck region
: Control Group 1
Initial diagnosis of a benign salivary gland tumor in the head and neck region
: Control Group 2
Healthy control group. Functional diseases of the nose or ear (patients with the indication for functional ear surgery and rhinoplasty) without salivary gland tumor.
Interventions
Other: - Sampling
Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
International Sites
Status
Recruiting
Address
Universitätsklinikum Erlangen, HNO
Erlangen, Bavaria, 91054
Site Contact
Sarina Mueller, PD
[email protected]
+49-9131-85 #43921
Status
Recruiting
Address
Universitätsklinikum Erlangen, Strahlenklinik
Erlangen, Bavaria, 91054
Site Contact
Marlen Haderlein, PD
[email protected]
+49913185 #33968
Privacy Overview